Vertex announces letter of intent with pan-Canadian Pharmaceutical Alliance for public reimbursement of CFTR modulators Extended to Include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

17 September 2021 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...

Read more →

Axsome Therapeutics announces FDA acceptance of new drug application for AXS-07 for the acute treatment of migraine

14 September 2021 - Axsome Therapeutics today announced that the U.S. FDA has accepted for filing the Company’s new drug application ...

Read more →

Limited access to 'lifesaving' cystic fibrosis drug Trikafta under Pharmaceutical Benefits Scheme

24 August 2021 - A mother whose son lives with cystic fibrosis says young people are dying as they wait for ...

Read more →

Cystic fibrosis patients, advocates urge Ontario government to provide ‘miracle drug’ funding

20 August 2021 - An Ontario teen living with Cystic Fibrosis and her mother are hoping to shine a light ...

Read more →

Halifax man devastated after insurer reverses decision to cover $25,000 cystic fibrosis drug

13 August 2021 - Stefan Strecko says he's pleaded with Canada Life to cover cost of 'miracle' drug. ...

Read more →

FDA grants first of its kind indication for chronic sleep disorder treatment

12 August 2021 - The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia in ...

Read more →

Jazz Pharmaceuticals announces U.S. FDA approval of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution for idiopathic hypersomnia in adults

12 August 2021 - Xywav is the first and only FDA approved treatment for idiopathic hypersomnia. ...

Read more →

Frustrated cystic fibrosis patient speaks out after drug coverage denial

30 July 2021 - Twenty eight year old cystic fibrosis patient Stefan Strecko says he went from jubilation to devastation ...

Read more →

Sol-Gel Technologies announces FDA approval of Twyneo

27 July 2021 - Twyneo utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038. ...

Read more →

New treatment authorised and available for Canadians with HER2 positive breast cancer

20 July 2021 - Phesgo, a fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection combines two treatments into ...

Read more →

Japan becomes first country to approve Regeneron antibody cocktail (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19

20 July 2021 - Regeneron Pharmaceuticals today announced that Japan's Ministry of Health, Labour and Welfare has approved Regeneron's casirivimab and ...

Read more →

G-BA sees “considerable additional benefit” in two active ingredients - EU HTA analysis is coming

15 July 2021 - The Federal Joint Committee (G-BA) today certified two active ingredients with a "considerable additional benefit". It assigns ...

Read more →

Cystic fibrosis patients upset over recommended restrictive criteria for life saving drug

15 July 2021 - 'By narrowly defining accessibility and continuation criteria CADTH’s recommendation overlooks many of Trikafta’s significant benefits,' says chief ...

Read more →

'A price on your life': Toronto cystic fibrosis patients slam review process while waiting for access to life-saving treatment

13 July 2021 - While Health Canada approved Trikafta for patient use on June 18, 2021, it is still not ...

Read more →

Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukaemia

7 July 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for ...

Read more →